Home Silk Road Medical Inc.

Silk Road Medical Inc.

ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile

Final Results Presented during the late-breaking session at the Society for Vascular Surgery Annual Meeting

TCAR Achieves Favorable Outcomes vs. Carotid Endarterectomy in Patients with Carotid Artery Disease

The TCAR Surveillance Project, a key initiative of the Society for Vascular Surgery’s Vascular Quality Initiative (VQI), is an open-ended registry intended to compare real-world patient outcomes between TCAR and CEA.

TCAR Presentations to Take Place at the Society for Vascular Surgery 2019 Vascular Annual Meeting

Key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcoming Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.

Silk Road Medical Traded its First Shares this Morning on Nasdaq: (SILK)

Silk Road Medical is focused on reducing the risk of stroke by treating carotid artery disease – a condition that affects more than 4 million people in the U.S. and is estimated to be the primary cause of up to one-third of strokes.

Silk Road Medical Announces Key TCAR Presentations at 2018 VEITHsymposium New York City

Silk Road Medical reports multiple podium presentations at the upcoming VEITHsymposium Nov. 13-17 at the New York Hilton-Midtown will feature the company’s TransCarotid Artery Revascularization (TCAR) procedure.

Updated TCAR Data from Silk Road Medical’s ROADSTER 1 and 2 Studies Presented at VEITHsymposium 2017

11/29/17: Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced multiple presentations at the 45th annual VEITHsymposium highlighting the safety and efficacy of the company's ENROUTE® Transcarotid Neuroprotection and Stent System, the first and only products specifically designed and indicated for TransCarotid Artery Revascularization (TCAR).

Updated TCAR Data from Silk Road Medical’s ROADSTER 1 and 2 Studies Presented at VEITHsymposium

“TCAR is the next step,” said Dr. Peter Schneider, Chief of Vascular Therapy at Hawaii Permanente Medical Group and Kaiser Foundation Hospital Honolulu, and National Co-Principal Investigator of the ROADSTER 2 post-market study. “Carotid endarterectomy has been perfected over 50 years, but no matter how good it gets, it has certain inherent challenges that aren’t ever going to go away. My attitude now has really flip-flopped from that of tried and true surgery to what I think is the future of carotid artery repair.”

Silk Road Medical Appoints World Class Stroke Prevention Champion to Serve as Vice President, Medical Affairs and Professional Education

HOME Tammy Leitsinger to spearhead global physician education and peer-to-peer training for rapidly growing Trans Carotid Artery Revascularization (TCAR) procedure Silk Road...